geneonyxdec202011:start
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| geneonyxdec202011:start [2015/05/06 18:43] – magiero | geneonyxdec202011:start [2015/05/06 18:46] (current) – magiero | ||
|---|---|---|---|
| Line 82: | Line 82: | ||
| • It can now be determined if an ingredient is efficient or not when affected by a specific SNP(s) in its target (the aforementioned __CROSS-VALIDATION__? | • It can now be determined if an ingredient is efficient or not when affected by a specific SNP(s) in its target (the aforementioned __CROSS-VALIDATION__? | ||
| • The final decision reflects the previously determined efficacy of the ingredient.\\ | • The final decision reflects the previously determined efficacy of the ingredient.\\ | ||
| - | • If the target is not functional the ingredient will not be recommended.\\ | + | • If the target is not functional the ingredient will not be recommended. |
| - | • In contrast, if the target is not affected by the SNP the ingredient will be recommended.\\ | + | • In contrast, if the target is not affected by the SNP the ingredient will be recommended |
| • If the SNP provides again enhanced efficacy of an ingredient, the dosage of this ingredient might be considered before being recommended\\ | • If the SNP provides again enhanced efficacy of an ingredient, the dosage of this ingredient might be considered before being recommended\\ | ||
| • taken into consideration is the genotype identified by the test. This will affect the correlation given on the efficacy of the test\\ | • taken into consideration is the genotype identified by the test. This will affect the correlation given on the efficacy of the test\\ | ||
geneonyxdec202011/start.1430937838.txt.gz · Last modified: 2015/05/06 18:43 by magiero